Functions of alpha-Synuclein in Neurotransmitter Release

α-突触核蛋白在神经递质释放中的功能

• 批准号: 8797356
• 负责人: Jianhua Xu
• 金额: $ 29.83万
• 依托单位: AUGUSTA UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-02-15 至 2018-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8797356
• 关键词: Action Potentials; Acute; Address; Affect; Binding; Brain; Calcium; Calcium Signaling; Calmodulin; Clinic; Clinical; Communication; Development; Disease; Dopamine; Early Diagnosis; Early treatment; Elderly; Electric Capacitance; Electrophysiology (science); Endocytosis; Excision; Exocytosis; Financial compensation; Foundations; Functional disorder; Future; Genetic; Goals; Health; Human; Impairment; Kinetics; Knock-out; Knowledge; Lewy Bodies; Lewy Body Dementia; Light; Link; Measurement; Membrane Proteins; Methods; Midbrain structure; Modeling; Molecular Target; Movement Disorders; Nerve; Nerve Degeneration; Nervous system structure; Neurodegenerative Disorders; Neuronal Dysfunction; Neurons; Parkinson Disease; Parkinson' s Dementia; Patch-Clamp Techniques; Patients; Peripheral; Presynaptic Terminals; Process; Property; Proteins; Recycling; Regulation; Resolution; Rest; S-nitro-N-acetylpenicillamine; Secondary Parkinson Disease; Signal Transduction; Staging; Symptoms; Synapses; Synaptic Transmission; Testing; Therapeutic; Vesicle; Work; alpha synuclein; base; cellular targeting; cysteine string protein; dopaminergic neuron; improved; knock-down; mutant; neurotransmission; neurotransmitter release; novel therapeutic intervention; overexpression; patch clamp; presynaptic; research study; syntaxin; synuclein; voltage

DESCRIPTION (provided by applicant): Parkinson's disease (PD) is the second most common neurodegenerative disease, which affects 1.8% of people over the age of 65 years. One clinic hallmark of PD is formation of intracellular proteinaceous inclusions, termed Lewy Bodies, in the brain neurons. The main constituent of the Lewy Bodies is alpha-synuclein, which is found to accumulate in neurons in both familial forms of PD and sporadic PD. Therapeutic strategies for PD patients have not been very successful, because clinical symptoms occur at a stage when the neuronal functions have been damaged to an extent hard to rescue. Improvement of the therapeutic strategies depends on better understanding of the pathophysiological development of PD, including presymptomatic neuronal dysfunctions induced by alpha-synuclein accumulation. Increased level of alpha-synuclein has previously been found to impair neurotransmitter release prior to the symptomatic PD. However, mechanisms causing such impairment are poorly understood. Because alpha-synuclein is mainly expressed in nerve terminals, which are usually too small for using the highly sensitive electrophysiology methods, previous studies could not directly evaluate contributions of many essential presynaptic factors, such as action potential, voltage dependent calcium entry, and vesicle recycling through endocytosis. In order to identify the primary cellular and molecular targets of elevated alpha-synuclein in nerve terminals, our studies will take advantage of the calyx of Held, a large mammalian synapse which is accessible to patch-clamp techniques. In preliminary experiments, we found that elevated alpha-synuclein inhibited vesicle exocytosis at the calyx synapse. This observation provides the foundation to further investigate the mechanisms underlying the inhibited exocytosis by elevated alpha-synuclein. In Aim 1, we will determine the interaction between elevated alpha-synuclein and calcium signaling. In Aim 2, we will determine whether elevated alpha-synuclein reduces exocytosis by affecting vesicle pool, endocytosis and mobilization. In Aim 3 we will determine whether the mechanisms identified at the calyx apply to midbrain dopaminergic neurons, which are related to the development of neurodegeneration. Achieving these aims can provide crucial information on how accumulation of alpha-synuclein causes the impairment of synaptic transmission prior to the symptomatic neurodegenerative disorders. This project can shed light on the process of pathophysiological changes in PD, and help the development of new therapeutic approaches targeting to these changes.

描述（由申请人提供）：帕金森病（PD）是第二常见的神经退行性疾病，影响1.8%的65岁以上人群。帕金森病的一个临床特征是在脑神经细胞中形成称为路易体的细胞内蛋白包涵体。路易小体的主要成分是α -突触核蛋白，在家族性帕金森病和散发性帕金森病的神经元中均发现其积累。PD患者的治疗策略一直不是很成功，因为临床症状发生在神经元功能受损到难以恢复的阶段。改善治疗策略取决于更好地了解PD的病理生理发展，包括由α -突触核蛋白积累引起的症状前神经元功能障碍。α -突触核蛋白水平的升高在症状性帕金森病之前已被发现损害神经递质释放。然而，造成这种损害的机制尚不清楚。由于α -突触核蛋白主要在神经末梢表达，而神经末梢通常太小，无法使用高灵敏度的电生理方法，因此以往的研究无法直接评估许多必要的突触前因子的贡献，如动作电位、电压依赖性钙离子进入和通过内噬作用进行囊泡循环。为了确定神经末梢α -突触核蛋白升高的主要细胞和分子靶点，我们的研究将利用Held的花萼，这是一种大型哺乳动物突触，可以使用膜片钳技术。在初步实验中，我们发现α -突触核蛋白的升高抑制了萼突触的囊泡胞吐。这一观察结果为进一步研究α -突触核蛋白升高抑制胞吐的机制提供了基础。在Aim 1中，我们将确定α -突触核蛋白升高与钙信号传导之间的相互作用。在Aim 2中，我们将确定α -突触核蛋白升高是否通过影响囊泡池、内吞和动员来减少胞吐。在Aim 3中，我们将确定在花萼中发现的机制是否适用于中脑多巴胺能神经元，这与神经变性的发展有关。实现这些目标可以为α -突触核蛋白的积累如何在症状性神经退行性疾病之前导致突触传递损伤提供关键信息。该项目可以揭示PD的病理生理变化过程，并有助于开发针对这些变化的新的治疗方法。